12:00 , May 20, 2019 |  BioCentury  |  Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

With a $50 million series A led by NEA and a management team guided by veterans of Shire takeout Lumena, Reneo believes its small molecule could carve out a niche in the rare genetic mitochondrial...
20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...
15:31 , Oct 4, 2018 |  BC Innovations  |  Translation in Brief

Risk Management Machinery

A Stanford University team has developed an AI platform that combines genomic and electronic health record data to help manage the risk of disease and identify new therapeutic targets. The group plans to out-license the...
16:34 , Mar 16, 2018 |  BC Week In Review  |  Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported data from the 18,924-patient Phase III ODYSSEY OUTCOMES trial showing that Praluent alirocumab given on top of statins lowered the risk of major adverse cardiovascular events...
14:36 , Mar 10, 2018 |  BC Extra  |  Clinical News

Sanofi, Regeneron offer lower Praluent price on heels of ODYSSEY data

Armed with cardiovascular outcomes data for Praluent alirocumab and a fresh cost-effectiveness analysis from the Institute for Clinical and Economic Review (ICER), Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) have a proposition for payers:...
23:04 , Feb 28, 2018 |  BC Extra  |  Preclinical News

The microbiome can predict disease risk

A study published in Nature shows the composition of an individual’s microbiome is controlled by environment and largely independent of genetics. It also shows microbiome make-up can predict disease states. Collectively, the findings suggest microbiome...
19:15 , Mar 13, 2017 |  BC Extra  |  Clinical News

Repatha reduces need for apheresis in Phase III study

Amgen Inc. (NASDAQ:AMGN) said Repatha evolocumab significantly reduced the need for apheresis among patients with high low-density lipoprotein cholesterol (LDL-C), meeting the primary endpoint of a Phase III study. Apheresis is a three- to four-hour...
07:00 , Jul 21, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Tetratricopeptide repeat domain 39B (TTC39B)

Cardiovascular disease INDICATION: Atherosclerosis; non-alcoholic steatohepatitis (NASH) Mouse studies suggest inhibiting TTC39B could help treat atherosclerosis and NASH. In mice fed a high-fat, high-cholesterol and bile salt diet, systemic or liver-specific TTC39B knockout increased serum...
07:00 , Apr 18, 2016 |  BioCentury  |  Regulation

Leading in liver

FDA is taking an active role in developing surrogate endpoints for liver diseases, and used an advisory panel meeting early this month to get advice on tackling some of the complexities involved. Companies working in...
00:40 , Apr 8, 2016 |  BC Extra  |  Top Story

FDA panel unanimously backs Intercept's Ocaliva

Members of FDA's Gastrointestinal Drugs Advisory Committee (GIDAC) voted 17-0 that there is substantial evidence to support accelerated approval of Ocaliva obeticholic acid ( OCA ) from Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) to treat primary biliary...